Mobile

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mise à jour : Il y a 4 ans
Référence : NCT02404220

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL). This study consists of two parts: Dose Escalation and Dose Expansion. After 2 induction cycles during either parts of the study, participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.

Critère d'inclusion

  • Acute Lymphoid Leukemia

Liens